Etoricoxib

Jump to: navigation, search
Etoricoxib
File:Etoricoxib.svg
Clinical data
Pregnancy
category
  • Not recommended
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability100%
Protein binding92%
MetabolismHepatic, CYP extensively involved (mainly CYP3A4)
Elimination half-life22 hours
ExcretionRenal (70%) and fecal (20%)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H15ClN2O2S
Molar mass358.842 g/mol

WikiDoc Resources for Etoricoxib

Articles

Most recent articles on Etoricoxib

Most cited articles on Etoricoxib

Review articles on Etoricoxib

Articles on Etoricoxib in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Etoricoxib

Images of Etoricoxib

Photos of Etoricoxib

Podcasts & MP3s on Etoricoxib

Videos on Etoricoxib

Evidence Based Medicine

Cochrane Collaboration on Etoricoxib

Bandolier on Etoricoxib

TRIP on Etoricoxib

Clinical Trials

Ongoing Trials on Etoricoxib at Clinical Trials.gov

Trial results on Etoricoxib

Clinical Trials on Etoricoxib at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Etoricoxib

NICE Guidance on Etoricoxib

NHS PRODIGY Guidance

FDA on Etoricoxib

CDC on Etoricoxib

Books

Books on Etoricoxib

News

Etoricoxib in the news

Be alerted to news on Etoricoxib

News trends on Etoricoxib

Commentary

Blogs on Etoricoxib

Definitions

Definitions of Etoricoxib

Patient Resources / Community

Patient resources on Etoricoxib

Discussion groups on Etoricoxib

Patient Handouts on Etoricoxib

Directions to Hospitals Treating Etoricoxib

Risk calculators and risk factors for Etoricoxib

Healthcare Provider Resources

Symptoms of Etoricoxib

Causes & Risk Factors for Etoricoxib

Diagnostic studies for Etoricoxib

Treatment of Etoricoxib

Continuing Medical Education (CME)

CME Programs on Etoricoxib

International

Etoricoxib en Espanol

Etoricoxib en Francais

Business

Etoricoxib in the Marketplace

Patents on Etoricoxib

Experimental / Informatics

List of terms related to Etoricoxib


Overview

Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a new COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1) from Merck & Co. Doses are 60, 90 mg/day for chronic pain and 120 mg/day for acute pain. Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Note that approved indications differ by country.

Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid. Among the different functions exerted by PGs, their role in the inflammation cascade should be highlighted. COX-2 selective inhibitor (aka "COXIB") showed less marked activity on type 1 cycloxigenase compared to traditional non-steroidal anti-inflammatory drugs (NSAID). This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet).

Some clinical trials and meta-analysis showed that treatment with COXIB led to increased incidence of adverse cardiovascular events compared to placebo. Because of these results, some molecules were withdrawn from the market (Rofecoxib, September 2004 and Valdecoxib, April 2005). In addition, the FDA and EMEA (USA and European Community Health Authorities respectively) started a revision process of the entire class of both NSAID and COX-2 inhibitors.

FDA concluded its revision on April 6, 2005: the final document can be found at: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf

EMEA concluded its revision on June 27, 2005: the final document can be found at: http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf

On April 27, 2007, the Food and Drug Administration issued Merck a "non-approvable letter" for Arcoxia. The letter said Merck needs to provide more test results showing that Arcoxia's benefits outweigh its risks before it has another chance of getting approved.


External links


nl:Etoricoxib


Linked-in.jpg